Trial Profile
Advanced breast cancer treatment with hR3 monoclonal antibody combined with doxorubicin and cyclophosphamide. Clinical trial, phase I.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2020
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Center of Molecular Immunology
- 13 Sep 2011 New trial record